If the safety of European patients is to be genuinely reinforced, the European Commission’s priorities must be to improve the quality of the evaluation of medicines before they are granted marketing authorisation and to increase the independence of drug regulatory authorities, to enable them to better fulfil their public health remit, particularly when evaluating and reviewing the harm-benefit balance of medicines. Read on...